Email alerts

Subscribe to our mailing list


Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW


Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Canada Humans Granted


Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.


Tri-Solfen® ‘effective treatment’ for foot and mouth disease

June 1, 2022
Mark Phelps

By Mark Phelps

June 1 2022 – 1:00pm

POPULAR over-the-counter pain relief product Tri-Solfen has emerged as an effective treatment for foot and mouth disease.

Writing on the Research Outreach website, Professor Emeritus Peter Windsor and his team at the University of Sydney said Tri-Solfen may be an inexpensive and effective solution to treat FMD, instead of the antibiotics currently used.

The World Organisation for Animal Health said the viral disease was estimated to circulate in more than 75 per cent of the livestock population in Africa, the Middle East and Asia, as well as parts of South America. Up to 32 million livestock around the globe are believed to become infected each year, costing an estimated $7 billion a year in lost production. The World Organisation for Animal Health said countries that were currently free of FMD without vaccination remained under constant threat of an outbreak. That’s of particular concern to Australia, given FMD was detected in near neighbour Indonesia earlier this year.

Prof Windsor said FMD came in seven strains and was a debilitating disease resulting in a fever that could last a few days typically followed by “incredibly painful” blisters on and inside the mouth and on the feet. The blisters caused lameness, excessive salivation, lack of appetite, loss of body condition and occasionally, mastitis and abortion.

“After clinical trials in Laos and Cameroon, results have shown emphatically that when Tri-Solfen is applied to FMD lesions, infected animals return to eating and walking normally within just a few days,” Prof Windsor said. “Sadly, in developing countries, farmers often don’t have access to preventative control programs including vaccinations and they seek treatment methods for their sick animals. In affected countries, use of antibiotics for FMD is common, but this approach increases the risk of creating long-term antimicrobial resistance with potential food safety risks when these animals are marketed. Sick animals can also be treated with painful disinfectants or anti-inflammatory drugs, but the benefits are limited. For the many farmers who don’t even have access to these, lesions caused by FMD are treated with painful traditional therapies, including scraping the lesions with tree bark or applying lemon juice. These options likely increase the pain and suffering animals have to endure during outbreaks.”

Developed in Australia as a pain relief treatment for common animal husband practices including dehorning and castration, Tri-Solfen contains two topical anaesthetics: lignocaine and bupivacaine, as well as adrenaline and cetramide, mixed in a distinctive blue gel. Tri-Solfen is applied directly to the nose and feet using a specially designed applicator gun, creating a lasting barrier over the lesions, numbing the pain, reducing infection and encouraging healing.

Prof Windsor said the acidic pH (around 2.7) coming from the antiseptic cetramide in the formulation also helped kill off the FMD virus. “The anti-bacterial properties in Tri-Solfen cleverly avoid the need for other treatments, including antibiotics and anti-inflammatories,” Prof Windsor said. “Furthermore, lignocaine and bupivacaine, combined with adrenalin, provide rapid and prolonged pain relief and alleviate the initial sting from applying such an acidic product. This pain-free effect is estimated to last over 24 hours and is sufficient to kill or reduce the virus load without causing pain to the animal.”

Prof Windsor said conclusive clinical trials in both the Laos and the Cameroon showed Tri-Solfen resulted in much faster healing of lesions caused by FMD. “Lesions in Tri-Solfen treated cattle with FMD significantly reduced in size and almost entirely disappeared in less than 10 days, without returning for a full two weeks after the initial infection,” Prof Windsor said. “As a consequence, these animals recovered their mobility without being lame and started eating almost immediately after treatment, suggesting this is a beneficial therapy to enable cattle to walk and gain access to water and feed.”

Prof Windsor said in contrast, while animals treated with oxytetracycline in the Cameron study also managed to heal most of their lesions, these tended to re-appear after two weeks, most likely from the onset of secondary infections, with some animals were still lame and struggling to walk after 15 days of symptoms.

“In an even worse situation, untreated animals had lesions that persisted and continued to enlarge for over two weeks, suggesting that healing was severely compromised and delayed,” Prof Windsor said. “Not surprisingly, these animals remained in pain and had poor appetite while they were sick, leading to profound loss of body condition. Some animals simply refused to move, and those that managed to walk were lame and struggling.”

Prof Windsor said importantly, Tri-Solfen product did not cost any more than the antibiotics or anti-inflammatories that it may replace, nor did it come with a warning of antimicrobial resistance or the presence of residues in the food chain. “Tri-Solfen treatment for FMD may change the way farmers treat infected cattle, shifting from expensive and inappropriate antibiotics to a solution that improves animal welfare and encourages farmers to report outbreaks,” he said. “As Tri-Solfen may increase the chances of farmers reporting outbreaks to obtain treatment of their animals, this assists disease surveillance and enables future vaccination delivery through extension advice.

“These observations indicate the huge potential of Tri-Solfen in having a profoundly positive impact on the health and welfare of livestock-owning families and their animals in the future. Of course animal health staff also need to maintain a focus on good hygiene practices to limit transmission from infected to uninfected animals. If made available for purchase and administration by farmers, this product provides a viable alternative approach for treating foot and mouth disease and in addition to vaccination and improved biosecurity, may assist disease control in Asian and African countries and other developing countries globally.”